VADS
CA223-001
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in;Advanced Refractory Solid Tumors
Paris
CHRISTOPHE LE TOURNEAU
VADS
COPAN-ORL 06
Phase Ib/II trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) harboring a PI3KCA mutation/amplification and/or a PTEN loss. COPAN - ORL06
Paris
CHRISTOPHE LE TOURNEAU
VADS
DEBIO 1143-201
A Phase I/II randomised study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio 1143 combined with concurrent chemo-radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Paris
CHRISTOPHE LE TOURNEAU
VADS
DEBIO 1143-202
Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck.
Paris
CHRISTOPHE LE TOURNEAU
VADS
U31287-A-U203 / Patritumab
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
Paris
CHRISTOPHE LE TOURNEAU
Prostate
MK3475-365
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Paris
Sein Adjuvant
MAGTRIVACSEIN - Projet MagTn3
An Open Label First-in-Human Adjuvant Phase I Study of a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri Tn Glycotop (MAG-Tn3) Plus AS15, as a Therapeutic Vaccine Candidate in Patients With Non Metastatic, HER2 Negative Localized Breast Cancer at High-Risk of Relapse
Paris
MARIE PAULE SABLIN
Appareil pulmonaire
SAFIR 02 Lung
Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer (Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung)
Paris
CATHERINE DANIEL